You are here: Industry Insights > ADC

News List

Piramal Invests $10 million in Riverview Expansion contractpharma
June 24, 2019
Expands High Potency API Capability to serve the growing ADC market.
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership en-cphi.cn
April 09, 2019
WuXi Biologics and NBE-Therapeutics (NBE) announced a comprehensive development and manufacturing partnership for NBE's first ADC lead product NBE-002 (anti-ROR1). NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment...
Iksuda Therapeutics and Femtogenix Sign License Agreement pharmafocusasia
March 07, 2019
Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.
Oxford BioTherapeutics Receives IND Clearance for OBT076 americanpharmaceuticalreview
December 24, 2018
Oxford BioTherapeutics has received US Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for OBT076.....
ADC Bio secures additional equity round investment cphi-online
November 27, 2018
ADC Biotechnology (ADC Bio) has secured additional funding of £2.5 million from existing investors and company management. The finance will be deployed to ensure the achievement of specific
ADC Bio Secures £2.5M Investment contractpharma
November 19, 2018
ADC Biotechnology(ADC Bio), announces that it has secured additional funding of 2.5 million from existing investors and
ADC Market to Grow to $4B contractpharma
October 10, 2018
A new analysis in the CPhI Annual Report estimates the increase in growth by 2023
ADC Therapeutics brings in $200 million of financing pharmafile
October 25, 2017
ADC Therapeutics has won some serious financial support after its latest financing round managed to net the company $200 million.
Glythera and IONTAS to collaborate for development of multiple antibodies for next-generation Antibo pharmaasia
September 26, 2017
This collaboration will capitalise on the Glythera ADC development expertise and Iontas' experience in antibody discovery services for optimal effect.
UK firms link to develop ADCs for cancer pharmatimes
September 21, 2017
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page